Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe

Wockhardt’s novel antibiotic Zaynich has a USD 7 billion market opportunity in the US and Europe, with regulatory filings and launches planned for FY2026-27.

Leave a Reply

Your email address will not be published. Required fields are marked *